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Abstract
Background: Conceptualisation and classification of functional disorders appear highly inconsistent in the health-care
system, particularly in primary care. Numerous terms and overlapping diagnostic criteria are prevalent of which many
are considered stigmatising by general practitioners and patients. The lack of a clear concept challenges the general
practitioner’s decision-making when a diagnosis or a treatment approach must be selected for a patient with a
functional disorder. This calls for improvements of the diagnostic categories. Intense debate has risen in connection
with the release of the fifth version of the ‘Diagnostic and Statistical Manual of Mental Disorders’ and the current
revision of the ‘International Statistical Classification of Diseases and Related Health Problems’. We aim to discuss a new
evidence based diagnostic proposal, bodily distress syndrome, which holds the potential to change our current
approach to functional disorders in primary care. A special focus will be directed towards the validity and utility criteria
recommended for diagnostic categorisation.
Discussion: A growing body of evidence suggests that the numerous diagnoses for functional disorders listed in the
current classifications belong to one family of closely related disorders. We name the underlying phenomenon ‘bodily
distress’; it manifests as patterns of multiple and disturbing bodily sensations. Bodily distress syndrome is a diagnostic
category with specific criteria covering this illness phenomenon. The category has been explored through empirical
studies, which in combination provide a sound basis for determining a symptom profile, the diagnostic stability and
the boundaries of the condition. However, as bodily distress syndrome embraces only the most common symptom
patterns, patients with few but impairing symptoms are not captured. Furthermore, the current lack of treatment
options may also influence the acceptance of the proposed diagnosis.
Summary: Bodily distress syndrome is a diagnostic category with notable validity according to empirical studies.
Nevertheless, knowledge is sparse on the utility in primary care. Future intervention studies should investigate the
translation of bodily distress syndrome into clinical practice. A particular focus should be directed towards the
acceptability among general practitioners and patients. Most importantly, it should be investigated whether the new
category may provide the basis for better treatment and improved clinical outcome.
Keywords: Bodily distress syndrome, Functional disorders, General practice, Diagnosis, Diagnostic utility, Diagnostic
validity, Medically unexplained symptoms
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Background
Many primary-care patients complain of symptoms
which cannot be attributed to any conventionally defined
medical disease or mental disorder [1–3]. Nevertheless,
the conceptualisation and classification of this phenomenon
appear to be highly inconsistent, particularly from a
primary-care perspective [4].
Numerous terms have been used for symptoms and
disorders without a medical diagnosis, e.g. medically unex-
plained symptoms (MUS), functional symptoms, functional
somatic syndromes, central sensitivity syndromes and
somatoform disorders. In this paper, we will use the term
‘functional disorders’ as an overarching descriptive term
embracing all these differently labelled conditions [5].
From a primary care perspective, there is a serious
need for a unifying diagnostic category for functional
disorders which should be both evidence based and ap-
plicable in the primary care setting. This paper discusses
the classification of functional disorders in primary care
and focuses on a new diagnostic concept and category of
moderate-to-severe functional disorders; bodily distress
syndrome (BDS). As we will show, this diagnosis is based
on an increasing amount of evidence and has the potential
to embrace the numerous conditions and syndromes cur-
rently being the source of ongoing debate and controversy
in this field. Hence, BDS may provide the needed im-
provement in classification of functional disorders.
Intense debate fuelled by an increasing demand for
improved diagnostic categories of functional disorders
were raging during the time leading up to and right after
the release of the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) [6], and discus-
sions are still ongoing now also in relation to the revision
of the International Classification of Diseases (ICD-10)
[7]. Without a well-defined concept and general agree-
ment on specific diagnostic categories, many patients with
functional disorders remain undetected and are not
offered adequate treatment [8]. This shortcoming exists
although these conditions are frequent; in the more severe
forms, the conditions are even persistent and associated
with significant disability, and high societal and health-
care costs [3, 9–17].
When patients present with functional disorders in
primary care, several circumstances prevent adequate
patient management. First, some general practitioners
(GP) and patients are sceptical about the concept of
functional disorders [18]. Second, there are tremendous
variations (3–33 %) in the awareness of the phenomenon
among GPs [19, 20]. Furthermore, neither the commonly
used term MUS nor the frequently used research method of
simply counting symptoms to identify functional disorders
are based on diagnostic criteria, and symptom counts have
been shown to be unreliable in clinical practice because of
the poor sensitivity and specificity of this approach [21].
The present diagnostic ICD-10 classification [7] in-
cludes numerous overlapping diagnoses within somatic
and psychiatric specialties [22–31], e.g. irritable bowel
syndrome, fibromyalgia and somatoform disorders. This
diagnostic overlap challenges the GP’s decision-making:
Which diagnosis and which referral programme out of
the many available would be the most suitable for this
particular patient? In addition, the somatoform diagnos-
tic categories presented in the psychiatric chapter of
ICD-10 are based on consensus and primarily target
severe and chronic cases, but these are rarely used in
primary care [20, 32]. These diagnoses are considered
stigmatising by many GPs and patients [33, 34]. The
DSM-5 diagnosis of complex somatic symptom disorder
(CSSD) [6], on the other hand, is more inclusive, but it
has been criticised for lack of specificity [35–37].
As a consequence of the lack of a consistent and valid
illness concept, and a suitable term for the phenomenon,
the ailing patient is labelled rather than the medical con-
dition (e.g. the ‘difficult patient’, the ‘frequent attender’
or the ‘heart-sink patient’). By naming and treating these
conditions differently from other medical conditions, we
may induce patient resistance. Patients seek the same
from their GP whether or not their symptoms can be ex-
plained by well-defined medical conditions; constructive
dialogue, tangible explanations for their symptoms, and
treatment and care [38, 39].
BDS was recently introduced as a diagnostic category.
BDS is an empirically based diagnostic category of func-
tional disorders, which encompasses most functional
somatic syndromes and somatoform disorders [2, 40].
Observational studies of BDS have been performed on
data from primary-care patients [2, 40–44], and results
from clinical trials have shown that BDS can serve as a
feasible diagnosis of functional disorders in specialised
health-care settings [45, 46]. BDS has influenced the
current diagnostic proposals for the ICD-11 because of
the empirical derivation [47]. We aim to present a brief
overview of the underlying concept of functional disor-
ders, which will be followed by an exploration of
whether BDS may be a valid and useful alternative to the
current diagnostic categories. We discuss whether BDS
fits the clinical phenomenon behind functional disorders
and whether this diagnostic category may be useful and
valid in primary care.
Discussion and conclusions
The nature of bodily distress
A growing body of evidence suggests that the many dif-
ferent functional somatic syndromes and somatoform
disorders listed in the current classifications belong to a
family of closely related disorders, or that they are ex-
pressions of the same underlying illness phenomenon
with various subtypes [2, 8, 40, 43, 48–50]. This illness
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phenomenon may be described as bodily distress and is
characterised by unpleasant and disturbing bodily sensa-
tions. The wide range of conditions labelled with different
names show striking similarities in symptom clustering
[2, 51], aetiology [48], pathophysiological mechanisms
[52], patient characteristics [53], treatment response [8]
and co-morbidity [40, 54].
Some studies have investigated how the phenomenon
of bodily distress presents. A part of these studies have
the major methodological advantage of being based on
exploratory approaches and not rely on existing defini-
tions. Across several independent studies from different
countries, similar symptom groups have been identified;
these represent gastrointestinal symptoms, musculo-
skeletal symptoms, cardiopulmonary symptoms, neuro-
logical/ general symptoms and urogenital symptoms
[2, 43, 51, 55–59].
Epidemiological research suggests that the differently
labelled conditions share a multifactorial aetiology compris-
ing interacting biological, psychological and environmental
factors [48, 60–62]. In other words, the conditions may best
be understood as a result of pathophysiological responses
to prolonged or severe mental and/or physical stress in
genetically susceptible individuals [8, 25, 60, 63–65]. It is
still unclear whether perpetuating factors, such as symptom
catastrophising and maladaptive coping, are primary or sec-
ondary phenomena (see Fig. 1). Some evidence suggests
that both genetic and environmental factors are correlated
with bodily distress; some are shared (and correlate with
the overall phenomenon), while others may be unique for
each subcategory of bodily distress [48, 66] and appear to
be primarily due to the environmental influences experi-
enced by each individual (see Fig. 2) [48, 67, 68]. Studies
have shown that 30-50 % of the patients with differently
Fig. 1 Etiopathogenesis of functional disorders. a CNS = central nervous system. Modified after Schröder and Dimsdale (2014)
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labelled functional disorders present with concurrent
mental disorders, particularly with depression and
anxiety [30, 40, 69]. Most studies on comorbidity
have been designed as cross-sectional studies and do
not allow for any causal interpretation between bodily
distress, anxiety and depression. Nevertheless, several
studies suggest that the genetic predisposition to de-
velop bodily distress is different from that of develop-
ing mental disorders [48, 53, 70, 71]. An increasing
volume of evidence indicates that biomedical and
neuropsychological processes initiate and maintain
bodily distress. Altered autonomic balance [63, 72],
stress-axis dysfunction [73–75], sensitised nervous
system [76, 77] and activated inflammatory response
[78] are all pathophysiological mechanisms that are
believed to have the potential to produce and maintain
physical symptoms. Finally, similar treatment strategies for
various syndromes targeting perpetuating factors appear to
be effective in terms of symptom relief and improved func-
tioning. These include exercise, psychological treatment,
information and structured care [25, 46, 79–81]. There is
some evidence from longitudinal studies that many pa-
tients with one functional disorder develop symptoms of
other functional disorders, i.e. there appears to be a high
degree of mobility between different functional disorders
over time [42, 82, 83]. Although we do not know the
details of the aetiology and pathogenesis, evidence points
strongly towards an underlying phenomenon of bodily
distress. A diagnostic category based on this concept may
improve the clinical diagnostics and provide a basis for the
needed explanatory models.
The diagnostic category of BDS
The diagnostic category of BDS is based on the symp-
tom groups pertaining to bodily distress and introduces
symptom pattern recognition as a core element of the
diagnostic criteria. This signifies that the clinician will
have to take the same approach as s/he would have done
in order to diagnose disease such as arthritis, appendi-
citis, ischemic heart disease, depression or lupus, i.e.
begin with a symptom and then inquire about other
symptoms known to be associated with the disease pat-
tern [84]. Patients with BDS present with a specific
symptom pattern of bodily distress, which is believed to
be associated with pathophysiological disturbances. The
symptom pattern is reliably identified by the presence of
Fig. 2 Model of underlying structure for shared predisposing genetic and environmental factors and co-morbidities. The specific syndromes appear
primarily to be due to particular environmental influences , e.g. the development of irritable bowel syndrome (IBS) subsequent to a bacterial
gastrointestinal infection. A-D are specific symptom clusters, e.g. cardiopulmonary, gastrointestinal, etc. UGF = unique genetic factors,
UEF = unique environmental factors
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multiple symptoms within specific symptom groups
[2, 40]. The characteristic symptom pattern, combined
with a time frame and impairment status, forms the
clinical diagnosis of BDS (see Table 1). The diagnostic
category comprises a multi-organ type and four single-
organ subtypes, and it does not require behavioural or
psychopathological features. The identification of BDS is
made solely through observation of clinical features,
but research to identify pathophysiological markers is
now being conducted.
How does BDS fulfil the principles of diagnostic validity
and clinical utility?
In the following, we discuss BDS in relation to the
accepted validators of clinical syndromes proposed by
Kendell, and Robins and Guze [85–87], the additional
criteria suggested by Fink and Rosendal [3, 88] and the
criteria for clinical utility proposed by Kendell and First
et al. [85, 89] (see Table 2).
The diagnostic validity and BDS
In favour of the validity of BDS is the fact that the clin-
ical description of the BDS symptom profiles originates
from principal component analyses analysis based on
data from a large study of 978 patients from internal
medical and neurological departments and from primary
care. The sample consisted of patients consecutively
referred to a neurological department (n = 120) and an
internal medical department (n = 157) during a three-
month period. From primary care consecutive patients
consulting 38 GPs on a new illness problem (n = 701)
were included. All participating patients were diagnostic-
ally interviewed using the Schedules for Clinical Assess-
ment in Neuropsychiatry (SCAN) [90]. This approach
entailed that not only a predefined list of symptoms
were assessed, but the 76 physical symptoms of the
physical health chapter of SCAN were explored. Results
from principal component factor analyses identified
three symptom groups across patients; a cardiopulmonary
group (including autonomic symptoms), a gastrointestinal
group and a musculoskeletal group (the fourth group of
general symptoms was introduced as described below).
However, BDS includes only the most common symptom
patterns of bodily distress, whereas, for example, genito-
urinary symptoms are not included. In addition, patients
with one symptom or very few, but significantly impairing,
symptoms will not fulfil the criteria for BDS. Conse-
quently, a group of patients suffering considerably from
single symptoms or multiple symptoms not belonging to
the described groups will still find themselves between
diagnostic categories. As a consequence of the methods
used, only fairly prevalent symptom groups were detected,
while rare conditions were not identified. Much larger
populations are required in order to identify infrequent
conditions.
The boundaries of BDS, i.e. the distinction between
patients with and without BDS, have been identified in a
study by Fink et al. using latent class analysis: The initial
analysis did not identify any boundaries as the patients
could not be divided into distinct groups. In addition,
the results showed that many patients presented with
unspecific general symptoms like fatigue and dizziness.
Adding a fourth symptom group (consisting of five general
unspecific symptoms) to the latent class analysis resulted
in the delineation of the BDS construct. Now BDS demon-
strated ability to discriminate between ‘no BDS’, ‘single-
organ BDS’ and ‘multi-organ BDS’. In other words,
patients were divided into three distinct groups as a result
of the statistical analyses. Patients with ‘multi-organ BDS’
presented with various symptoms originating from several
bodily systems, whereas patients with ‘single-organ BDS’
presented symptoms from one or two bodily systems.
‘Single-organ BDS’ was characterized by the bodily
systems involved, i.e. gastrointestinal, cardiopulmonary,
musculoskeletal or general symptoms [2].
The typical course of BDS has been described in two
follow-up studies [42, 44]. Results from primary care
indicate that the condition is rather persistent and that
patients with BDS are generally at high risk of poor out-
come. Persistency was measured during two years of
follow-up, and the results showed that more than half of
the patients with BDS at baseline still met the criteria
for BDS at follow-up [42]. In comparison, studies on
functional somatic syndromes have shown a two-year
Table 1 Diagnostic criteria for BDS
1) ≥ 3 symptoms from at least one of the following groups:
• Cardiopulmonary/autonomic arousal:
Palpitations /heart pounding, precordial discomfort, breathlessness
without exertion, hyperventilation, hot or cold sweats, dry mouth
• Gastrointestinal arousal:
• Abdominal pains, frequent loose bowel movements, feeling bloated/
full of gas/distended, regurgitations, diarrhea, nausea, burning
sensation in chest or epigastrium
• Musculoskeletal tension:
• Pains in arms or legs, muscular aches or pains, pains in the joints,
feelings of paresis or localized weakness, back ache, pain moving from
one place to another, unpleasant numbness or tingling sensations
• General symptoms:
Concentration difficulties, impairment of memory, excessive fatigue,
headache, dizziness.
2) The patient has been disabled by the symptoms (i.e. daily living is
affected)
3) Relevant differential diagnoses have been ruled out
• Severity:
Single-organ BDS (mild-moderate): involves one or two of the
symptom groups
Multi-organ BDS (severe): involves three or four of the symptom
groups
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persistency of chronic widespread pain of 35 % (community
population) and a 12-month persistency of chronic fatigue
syndrome of 70 % (primary-care population) [91, 92].
Furthermore, a primary-care study with 10-year follow-up
showed that BDS was associated with an increased risk of
dropping out from the labour market and of receiving
public disability benefits [44]. However, a more ad-
vanced classification may further specify illness course
(episodic, chronic with increasing impairment, chronic
with stable impairment, etc.
Two therapeutic trials have been completed [45, 46],
and others are currently being conducted on patients
with multi-organ BDS. The trials investigate the effect of
specialised treatments such as cognitive behavioural
therapy, acceptance and commitment therapy, mindfulness-
based stress reduction and antidepressants [93]. However,
therapeutic trials of patients with single-organ BDS remain
to be conducted in a primary-care setting. Studies on family
prevalence and potential associations with pathophysio-
logical abnormalities are also lacking in order to further
estimate the validity of BDS as a diagnostic concept.
The additional validity criteria and BDS
The population used for developing the BDS diagnosis is
partly representative of primary care as the BDS criteria
were based on empirical data from both primary- and
secondary-care populations. The data was adequately
collected, and the assessment was made in accordance
with the procedure for diagnostic SCAN interviews. Re-
garding a cross-validation of the diagnosis, it is worth
mentioning that symptom groups and patient severity
groups similar to those of BDS have been identified in
several studies [49–51, 55–58, 94]. In addition, the BDS
construct has been confirmed in a primary-care popula-
tion (n = 2480) by use of factor and latent class analyses.
[43]. However, further studies conducted in different set-
tings and countries are needed in order to consolidate
these tentative findings. Furthermore, it has been tested
whether patients with six specific functional somatic syn-
dromes (chronic fatigue syndrome, fibromyalgia, irritable
bowel syndrome, non-cardiac chest pain, hyperventilation
syndrome and pain syndrome) and the DSM-IV somato-
form disorders characterised by physical symptoms also
Table 2 Validators and utility of clinical syndromes, as well as established evidence regarding BDS
Validator Scientific method Study
Identify and describe the syndrome ‘Clinical intuition’ or cluster analyses Fink et al. (2007) [2] Budtz-Lilly et al. (2015) [43]
Demonstrate boundaries between
related syndromes and from normality
Statistical methods, e.g. latent class analysis Fink et al. (2007) [2] Budtz-Lilly et al. (2015) [43]
Establish a distinct course or outcome Follow-up studies Budtz-Lilly et al. (2015) [42] Rask et al. (2015) [44]
Establish a distinct treatment response Therapeutic trials Fjordback et al. (2013)a [45] Schröder et al. (2012)a
[46]
Establish that the syndrome ‘breeds
true’
Family studies No studies found
Identify biological correlates Demonstrate the association with abnormalities of
anatomical, biochemical or molecular character
No studies found
Additional validator Study
The patients must be sampled from
representative populations
Fink et al. (2007) [2] Budtz-Lilly et al. (2015) [42]
Budtz-Lilly et al. (2015) [43] Rask et al. (2015) [44]
Results should be confirmed in cross-
validation studies
Budtz-Lilly et al. (2015) [43]
Patients must be assessed by an
appropriate method
Fink et al. (2007) [2]
Clinical utility Study
Is it used? No studies found
Is it acceptable to users? Lam et al. (2013) [84]
Is it easy to use? No studies found
Is it used correctly? No studies found
Does it improve clinical outcome? No studies found
Does it enhance communication?
with patients No studies foundb
across medical specialties No studies found
Does it assist in conceptualising? Lam et al. (2013) [84]
aSpecialised setting
bApplies explanatory models
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met the criteria for BDS. The overall diagnostic agreement
between BDS and the investigated diagnoses was 95 %
(95 % CI: 93.1–96.0, kappa 0.86, p < 0.0001) [40]. These
findings indicate that BDS may capture the different
diagnoses that appear across the different chapters of
the ICD-10 and the somatoform disorders classified
according to the (now outdated) DSM-IV.
The clinical utility and BDS
According to Kendell, a diagnostic category possesses
utility when it provides non-trivial information about
prognosis, treatment outcomes, and/or testable proposi-
tions about biological and social correlates (aetiology)
[85]. First et al. proposed a more detailed definition of
clinical utility as the extent to which a diagnostic classifi-
cation assists the clinical decision-makers in conceptua-
lising and communicating clinical information, using the
diagnostic categories, choosing effective interventions
and predicting future management needs [89]. The
clinical utility of a diagnostic category may be assessed by
posing the following questions: Is it used? Is it acceptable
to users? Is it easy to use? Is it used correctly? Does it im-
prove the clinical outcome? (See Table 2).
So far, it has not been described to what extent BDS is
(would be) used in everyday general practice. This is
partly because BDS is a new diagnostic category which
has not yet been incorporated in the current diagnostic
classification systems, and partly because the construct
of BDS has not been investigated in implementation
studies. In most countries, the health-care system does
not offer sufficient (if any) treatment programmes for
patients with functional disorders. This would affect the
diagnostic utility of any diagnosis. If no treatment op-
tions are available, or a diagnostic category has direct
negative consequences for the patient, the GP will obvi-
ously be reluctant to use such a diagnosis. The lacking
treatment options may also lead to low acceptance of
BDS and, ultimately, increased risk of stigmatisation.
The user acceptability of BDS has been explored in
focus group interviews about general views on the diag-
nosis among GPs; these interviews were completed in
seven countries in connection with the upcoming pri-
mary health-care version of the ICD-11 on mental
health. There was general agreement that this dis-
order does exist, but no clear consensus was reached
on the proposed diagnostic criteria [84]. Further rat-
ing of user acceptability and translation of BDS into
clinical practice is currently being conducted in field
trials worldwide under the auspices of the World
Health Organisation [84].
Whether BDS is easy to use in general practice re-
mains to be examined. However, the fact that BDS has a
clear classification algorithm, and that a diagnostic aid,
the BDS checklist, has been developed, is in favour of
the feasibility [43]. Also the improved conceptualisation
provided through theoretically based hypotheses on aeti-
ology may form the basis for a set of explanatory models
which could serve as satisfactory candidates for both
physicians and patients [84, 95, 96].
Furthermore, whether BDS is used correctly or, most
importantly, whether BDS may lead to an improvement
of the clinical outcome for patients with functional dis-
orders remains to be investigated.
Patient acceptability
Data collected for clinical assessment of patients with
multi-organ BDS show a high degree of patient accept-
ability [97], and multi-organ BDS has been used as an
inclusion criterion in several clinical trials with low
drop-out rates [45, 46]. It is unknown whether the re-
ported acceptability is generalisable to other patient
groups.
Are psycho-behavioural characteristics a prerequisite for
the diagnostic criteria?
It is often discussed whether psycho-behavioural charac-
teristics should form part of the diagnostic criteria for
functional disorders [47]. BDS has been shown to include
most patients with somatoform disorders, even when
psycho-behavioural characteristics are not included in the
diagnostic criteria [40]. This may indicate that although
behavioural and cognitive factors are associated with
pathogenesis of functional disorders [60], they may not be
prerequisite as diagnostic criteria.
Terminology
A useful diagnostic category may improve the clinical
communication. In this regard, terminology is closely
linked to classification as names convey information and
meaning by their etymology, associations and connota-
tions [95]. An international group of experts has recom-
mended using a non-stigmatising term, which should be
neutral in terms of aetiology and pathology, for this
diagnosis; bodily distress syndrome has been considered
an option [5]. The term is meant to be descriptive of
patient complaints and yet more constructive than
‘medically unexplained symptoms’, a label that many
patients find hard to accept [84]. Yet, the recent ter-
minology discussions have also given rise to some
concerns with respect to use of the word ’distress’. In
some languages, e.g. English, ‘distress’ is generally associ-
ated with a description of emotional states [5, 84, 98]
rather than a description of a physically impaired state.
The terminology discussion seems to continue, even after
the proposition of BDS, which is probably because the
meaning of the term may vary depending on language and
cultural context.
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Does BDS enhance a non-dualistic approach to functional
disorders?
Some authors seem to regard BDS as a diagnosis which
does not enhance a non-dualistic clinical approach be-
cause other relevant differential diagnoses must first be
ruled out in order to diagnose a patient with BDS [47].
Two issues will be addressed regarding this viewpoint.
First, it is the symptom pattern and not each individual
symptom which should be assessed as ‘functional’ or
not. This differs from the classification of the current
somatoform disorders in the ICD-10; when a clinician
decides to apply one of these diagnoses, each symptom
must be assessed as either ‘functional’ or ‘of medical ori-
gin’. For a BDS diagnosis, the symptoms and the pattern
they form must be considered in combination. The
physician must, therefore, inquire about symptoms of
BDS to identify a characteristic illness picture in the
same way as for the diagnostic work-up of any medical
or psychiatric condition. It appears less futile to assess
whether the expression of the condition as a whole most
likely is caused by a well-defined medical condition
because a symptom pattern is more specific than single
symptoms; symptoms that in the case of functional dis-
orders are often vague and very common. Second, every
time a clinician reaches any diagnosis for a patient
several differential diagnoses must first be taken into
consideration and a disease hypothesis must be tested.
In this sense, BDS is not any different.
Summary
BDS is a diagnostic category that fulfils several import-
ant validators for clinical syndromes. However, the
current knowledge on the utility of the diagnosis is
sparse, and BDS has, so far, been implemented only in
specialised health-care settings. Future intervention
studies should investigate the translation of BDS into
clinical practice and should direct a special focus on the
acceptability of the BDS construct among GPs and pa-
tients; whether it is used and, most importantly, whether
it seems to guide treatment and improve the clinical
outcome for the affected patients. However, in order to
evaluate the performance and the required adaptation of
the BDS construct, training of the health-care profes-
sionals is essential, as it is when any new concept is
introduced in clinical practice.
A major advantage of the BDS diagnosis is that it has
been explored in empirical studies, including primary-
care populations. On the other hand, BDS does not em-
brace all patients with impairing symptoms; a small
group of patients with either rare functional symptom
patterns or only very few disabling symptoms (or just
one disabling symptom) are not included in the category.
In addition, all studies on BDS have been conducted in
countries of the Western world. The lacking knowledge
of the validity of BDS in the developing countries is a
drawback. However, field trials studies are being per-
formed worldwide including primary care populations
from Brazil, Mexico, Spain, Pakistan and Hong Kong
under the auspices of World Health Organization. Finally,
the term itself may be a challenge as it translates poorly
into some languages and may contribute to dualism, e.g.
the word ‘distress’ may, in some cultural contexts, primar-
ily imply emotional aspects.
Reactions to diagnoses of functional disorders vary
broadly and there is a need to find common ground and
concept. The BDS concept may offer an evidence-based
path for uniformly categorising patients with functional
disorders and may help relieve some of the classification
confusion caused by the existing numerous overlapping
labels. Furthermore, BDS may provide the GP with a
diagnosis which is more suitable for the clinical picture
seen in general practice and opens up for tangible ex-
planatory models. In combination, this may entail more
consistent patient management and may also form the
basis for more homogeneous research in prevention and
improved treatment strategies; hence BDS holds the po-
tential for better patient outcomes.
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